SCHEMBL17830723

SCHEMBL17830723

Cc1cccc(COC(=O)Cn2c(=O)oc3cc(Cl)ccc32)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
POLB P06746 2/20 0.51
MIF P14174 2/20 0.50
ALDH1A1 P00352 2/20 0.49
USP2 O75604 1/20 0.49
MAPT P10636 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
TP53 P04637 3/20 0.47
TSHR P16473 1/20 0.47
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HSP90AA1 P07900 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
IDO1 P14902 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830725 0.91 POLB (0.52) POLBALDH1A1USP2MAPTTP53
SCHEMBL17830736 0.89 MIF (0.52) POLBMIFALDH1A1USP2MAPT
SCHEMBL17830722 0.88 RECQL (0.55) PKMPOLBMIFALDH1A1USP2
SCHEMBL17830715 0.88 PIK3CB (0.54) POLBMIFALDH1A1USP2MAPT
SCHEMBL17830720 0.88 TP53 (0.56) POLBMIFALDH1A1USP2MAPT
SCHEMBL17830727 0.88 IDO1 (0.55) PKMPOLBALDH1A1USP2MAPT
SCHEMBL17830724 0.86 IDO1 (0.51) POLBALDH1A1USP2MAPTTP53
SCHEMBL17830729 0.85 CYP1A2 (0.45) POLBALDH1A1USP2MAPTTP53
SCHEMBL17830735 0.84 CCR2 (0.48) POLBALDH1A1USP2MAPTTP53
SCHEMBL5298443 0.84 MIF (0.64) PKMPOLBMIFALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A PKM 3507/4885POLB 2366/4885MIF 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.